Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Primary FSGS
NCT04983888Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2021
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in focal segmental glomerulosclerosis (FSGS), sponsored by Mayo Clinic. Primary endpoint: Change in Proteinuria at 24 months. Started Nov 2021; status: completed.
02
Drugs
obinutuzumab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT04983888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983888.